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 Introduction 
Gliomas that show a gliomatosis cerebri growth pattern constitute several diffuse 
glioma subtypes that are characterized by exceptionally widespread involvement of 
three or more cerebral lobes (8). Due to the diffusely infiltrating nature and the 
preservation of the anatomic architecture of the surrounding normal tissues, the extent 
of surgical resection is usually quite limited. Therefore, these gliomas remain clinically 
challenging and have an extremely poor prognosis with a median survival ranging 14.5 
to 18.5 months (4, 15). Gliomas with similar extensive diffuse infiltration from the 
cerebellum to the brainstem in the absence of cerebral cortical involvement have also 
been reported as an extremely rare entity. This entity was termed gliomatosis cerebelli, 
and to the best of our knowledge, only four cases have been described to date (3, 9, 11, 
13). Given the rarity of these tumors, the clinical characteristics and prognosis of 
gliomatosis cerebelli are unclear, and the optimal treatment strategy is also undefined. 
Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal 
antibody that exerts potent anti-angiogenic effects and normalization of vascular 
permeability (1). Administration of bevacizumab induces a decrease in contrast 
enhancement of the tumor and peritumoral edema on magnetic resonance imaging 
(MRI), leading to improved progression-free survival and maintenance of baseline 
quality of life (5). Based on the fundamental mechanism of the antitumor effect of 
bevacizumab, patients with highly neovascularized tumors are commonly considered to 
be good candidates for bevacizumab treatment (7). In contrast, diffusely infiltrating 
gliomas without a definite mass, such as gliomas with the gliomatosis cerebri growth 
pattern, have poor neovascularization and are expected to be less likely to respond to 
bevacizumab treatment. However, these issues remain uncertain because few previous 
 reports have discussed the efficacy of bevacizumab for gliomas with the gliomatosis 
cerebri growth pattern, and no reports have described diffusely infiltrating cerebellar 
gliomas. 
We report a case of diffuse cerebellar anaplastic astrocytoma with the gliomatosis 
cerebelli growth pattern that was successfully controlled with bevacizumab after rapid 
progression during concomitant chemoradiotherapy. 
 
Case report 
A 75-year-old man suffered from vertigo and headache for 2 months. He visited a 
nearby hospital because of the rapidly progressive nausea and dysarthria. His medical 
history included hypertension and atrial fibrillation. He was referred to our hospital 
because computed tomography revealed a relatively homogeneous low-density area in 
the right cerebellar hemisphere and the brainstem. On admission, neurological 
examination showed dysarthria, nystagmus, and right cerebellar ataxia. MRI revealed a 
poorly demarcated high-signal intensity on T2-weighted images and fluid-attenuated 
inversion recovery images in the right cerebellum and the brainstem (Fig. 1A-1, 2). The 
tumor in the right cerebellum showed sparse enhancement with gadolinium (Gd) on 
T1-weighted images (Fig. 1A-3). Magnetic resonance spectroscopy showed elevation of 
the choline/creatine peak ratio, a decrease in the N-acetyl-L-aspartic acid peak, and 
weak detection of the lactate signal. 
Because of the rapid progression of symptoms and the severe tonsillar herniation 
demonstrated on MRI (Fig. 1A-5), suboccipital decompressive craniotomy and partial 
removal of the tumor in the right cerebellar hemisphere and cerebellar tonsil was 
emergently performed. The tumor component that demonstrated sparse Gd enhancement 
 on MRI showed positive fluorescence with intraoperative photodynamic diagnosis using 
5-aminolevulinic acid; the other components showed negative fluorescence. 
On histopathological examination, the tumor cells had mainly spread throughout the 
white matter, and were less apparent in the granular, Purkinje cellular, and molecular 
layers in the cerebellar cortex (Fig. 2A, B). The anatomical structures were preserved in 
the infiltrated white matter tissues. The tumor cells had spindle-shaped nuclei, and some 
nuclei showed an atypical shape (Fig. 2C, D). Little mitosis (1/10 high-power field) was 
seen, and no evidence of necrosis or neovascularization was present. The MIB-1 index 
positivity was 9% (Fig. 3A), and the tumor cells were positive for glial fibrillary acidic 
protein (GFAP) and S100 with immunohistochemistry. Immunohistochemical analysis 
also revealed retained ATRX expression but no p53 overexpression (Fig. 3B, C). The 
MGMT promoter methylation status as assessed by methylation-specific PCR was 
unmethylated. Further genomic analyses using pyrosequencing revealed no mutation in 
IDH1, H3F3A, or BRAF. The pathological diagnosis was anaplastic astrocytoma, IDH 
wildtype. 
The patient received treatment with radiotherapy (60 Gy/30 fr) and concomitant 
temozolomide. However, 5 days after the start of the treatment, rapid worsening of 
dysarthria and dysphagia was seen. MRI that was performed 7 days after the start of the 
treatment showed significant enlargement of the T2 high-intensity area that extended 
into the cerebral peduncle and a new lesion with Gd enhancement in the midbrain (Fig. 
1B).  
Therefore, bevacizumab was administered at 10 mg/kg every 2 weeks beginning 11 
days after the start of postoperative treatment. After administration of bevacizumab, the 
neurological symptoms gradually improved, the T2 high-intensity area decreased, and 
 the Gd-enhancing lesion disappeared, as shown on MRI (Fig. 1C). After completing 
concomitant chemoradiotherapy, the patient was discharged with residual symptoms of 
mild dysarthria and unsteadiness. Adjuvant temozolomide was administered according 
to the Stupp regimen for 1 year, and bevacizumab was continued every 2 weeks in the 
outpatient clinic. At follow-up 2 years after the operation, no worsening of the 
neurological symptoms was seen, and the residual T2 high-intensity area remained 
unchanged without detection of a new Gd-enhancing lesion on MRI (Fig. 1D). 
 
Discussion 
The present case illustrates a diffusely infiltrating cerebellar anaplastic astrocytoma 
without a discernible mass that was effectively controlled with bevacizumab for 2 years, 
even after rapid progression during standard chemoradiotherapy. This case showed 
several remarkable features. First, this glioma with the gliomatosis cerebelli growth 
pattern showed rapid progression, even with standard chemoradiotherapy. Second, 
bevacizumab was an effective treatment for this diffuse glioma without a definite mass 
in the cerebellum. To the best of our knowledge, this is the first report demonstrating 
the efficacy of bevacizumab for a diffusely infiltrating cerebellar glioma. 
The tumor in the present case was pathologically diagnosed as an anaplastic 
astrocytoma that diffusely involved the right cerebellum and brainstem without 
mass-like expansion. From the fact that H3K27M mutation which strongly supports a 
diagnosis of a diffuse midline glioma was not detected in genomic analysis, the most 
aggressive lesion represented with Gd enhancement only primarily localized in the right 
cerebellum, and cranial nerve dysfunction was absent as an initial symptom, the tumor 
may have originated in the right cerebellum and subsequently infiltrated into the 
 brainstem (8, 14). In this regard, the present tumor was considered to exhibit the 
gliomatosis cerebelli growth pattern as previously reported (3, 9, 11, 13). A diffuse 
glioma originating in the cerebellum and infiltrating into the brainstem, termed 
gliomatosis cerebelli by Rorke et al., is extremely rare, and only four cases have been 
reported (3, 9, 11, 13). Three reported pediatric cases showed a relatively favorable 
clinical course without progression following various treatments including one patient 
who underwent two partial resections, one patient who underwent a biopsy followed by 
temozolomide, and one patient who underwent partial resection followed by 
chemoradiotherapy (3, 9, 13). In contrast, one reported case of an elderly patient 
showed a poor clinical course without intensive treatment because of her low 
performance status (11). The present case has several similarities with the latter reported 
case including the elderly-onset age, positive immunoreactivity for GFAP, and clinical 
aggressiveness. Reported cases with gliomatosis cerebelli showed a highly variable 
clinical course, and a subset of such cases may progress rapidly. Likewise, a subset of 
gliomas with the gliomatosis cerebri growth pattern responds poorly to standard 
chemoradiotherapy following biopsy, leading to unfavorable outcomes (6, 12). Taken 
together, further investigation will be required to determine the appropriate treatment 
for diffuse gliomas showing the gliomatosis cerebelli or gliomatosis cerebri growth 
pattern, particularly in clinically aggressive cases. 
Bevacizumab treatment is associated with two controversial issues about its efficacy. 
First is the efficacy for gliomas located in the cerebellum, and the second is for diffuse 
gliomas with the gliomatosis cerebri growth pattern. We previously reported no 
significant difference in survival time following bevacizumab treatment between 
patients with supratentorial recurrent malignant gliomas and those with infratentorial 
 recurrent malignant gliomas, suggesting the potential applicability of bevacizumab 
treatment for cerebellar gliomas (10). However, no other previous reports have focused 
on the efficacy of bevacizumab for cerebellar gliomas. With respect to the efficacy of 
bevacizumab for diffusely infiltrating gliomas represented by gliomas with the 
gliomatosis cerebri growth pattern, it seems doubtful if bevacizumab exerts therapeutic 
effects for those gliomas by affecting neovascularization, because diffusely infiltrating 
tumor cells, which are seen as non-contrast-enhancing tumors on MRI, may not depend 
on tumor neovasculature. In recent years, however, Burger et al. reported that diffusely 
infiltrating tumors do respond to bevacizumab treatment and that the effect of 
bevacizumab on contrast-enhancing and non-contrast-enhancing tumors was similar in 
most of their patient series (2). They concluded that bevacizumab should not be 
withheld from diffusely infiltrating gliomas because a significant proportion of patients 
with gliomatosis-like or non-gliomatosis-like gliomas obtain some clinical benefit from 
bevacizumab treatment (2). In the present case with a diffusely infiltrating anaplastic 
astrocytoma involving the cerebellum and the brainstem, bevacizumab provided a 
significant, long-term treatment effect for this aggressive tumor that showed resistance 
to standard concomitant chemoradiotherapy in the introduction period. Although the 
long-term treatment effect may be attributed to concomitant and adjuvant 
chemoradiotherapy with temozolomide as well as bevacizumab treatment, bevacizumab 
played a critical role in controlling this aggressive tumor particularly in the introduction 
period of standard treatment. Taken together, these findings from the present case and 
the previous reports indicate that bevacizumab treatment may be a salvage treatment 
option for patients with diffusely infiltrating cerebellar gliomas that exhibits rapid 
progression during standard treatment. 
  
Conclusion 
Gliomas that show extensive diffuse infiltration from the cerebellum to the brainstem 
without a definite mass are extremely rare. Although the tumor characteristics remain 
uncertain due to their rarity, we should be aware that those gliomas have the potential 
for rapid progression due to resistance to standard chemoradiotherapy. Bevacizumab 
treatment may be a treatment option for this type of clinically aggressive tumor. 
  
 Figure legends 
Figure 1  
 (1) Axial T2-weighted images (T2WI), (2) coronal fluid-attenuated inversion recovery 
images (FLAIR), (3, 4) axial T1-weighted images with gadolinium (Gd-T1WI), and (5) 
sagittal Gd-T1WI. 
(A) Preoperative magnetic resonance imaging (MRI) 
MRI demonstrated a poorly demarcated high-intensity lesion on T2WI and FLAIR in 
the right cerebellum and the brainstem. Gd-T1WI showed sparse enhancement in the 
tumor of the right cerebellum (short arrow) and tonsillar herniation (long arrow). 
(B) MRI 7 days after the start of standard chemoradiotherapy treatment  
MRI showed enlargement of the high-intensity area (curved arrow) and extension to the 
cerebral peduncle (arrowhead) on T2WI and FLAIR and new Gd enhancement in the 
midbrain (short arrow). 
(C) MRI 15 days after initial administration of bevacizumab 
MRI showed shrinkage of the high-intensity area on T2WI and FLAIR and 
disappearance of the Gd-enhancing lesion. 
(D) MRI 2 years after the operation 
MRI demonstrated no change in the residual high-intensity area on T2WI and FLAIR 
and no evidence of a Gd-enhancing lesion. 
 
Figure 2  
(A, B) Photomicrographs showed tumor cells that were mainly dispersed in the white 
matter. (C, D) Photomicrographs demonstrated that the tumor cells have spindle-shaped 
 nuclei, some of which showed an atypical shape. Hematoxylin and eosin staining 
(A-D); magnification ×12.5 (A), ×40 (B), ×100 (C), and ×400 (D). 
 
Figure 3 
(A) The MIB-1 labelling index was 9%. (B) Immunohistochemical analysis showed that 
ATRX expression was retained. (C) Immunohistochemical analysis showed negative 
p53 overexpression. Magnification ×100 (A-C). 
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Abstract  
Background: Gliomas that show extensive diffuse infiltration from the cerebellum to the 
brainstem without mass-like expansion are extremely rare. The efficacy of bevacizumab 
treatment for diffusely infiltrating gliomas remains uncertain. 
Case Description: A 75-year-old man presented with a cerebellar anaplastic astrocytoma 
showing diffuse infiltration to the brainstem without a definite mass. He had experienced 
rapidly progressive nausea and dysarthria as well as vertigo and headache for 2 months. 
Magnetic resonance imaging (MRI) revealed a poorly demarcated T2 high-intensity area 
in the right cerebellum and brainstem. The tumor in the right cerebellum showed sparse 
enhancement with gadolinium (Gd). Suboccipital decompressive craniotomy and partial 
removal of the tumor was emergently performed because of the rapid progression of 
symptoms and the severe tonsillar herniation demonstrated on MRI. The pathological 
diagnosis was anaplastic astrocytoma, and genomic analyses revealed no mutation in 
IDH1, H3F3A, or BRAF. During concomitant chemoradiotherapy with temozolomide, 
rapid worsening of the neurological symptoms developed, and significant enlargement of 
the T2 high-intensity area extending to the cerebral peduncle was seen, as well as a new 
Gd-enhancing lesion in the midbrain. After administration of bevacizumab, the 
neurological symptoms gradually improved, the T2 high-intensity area decreased, and the 
Gd-enhancing lesion disappeared. At follow-up 2 years after the operation, no worsening 
of neurological symptoms was seen, and the residual T2 high-intensity area remained 
unchanged on MRI. 
Conclusions: Bevacizumab treatment may be a salvage treatment option for patients with 
diffusely infiltrating cerebellar gliomas that exhibits rapid progression during standard 
treatment. 



